Evidence map›Paper›PMID 32423469›Full record

ArticleParasites & vectors2020

Therapeutic efficacy of Schistosoma japonicum cystatin on sepsis-induced cardiomyopathy in a mouse model.

Shifang Gao, Huihui Li, Hong Xie, Shili Wu, Yuan Yuan, Liang Chu, Siying Sun, Huijuan Yang, Lingqin Wu, Yongsheng Bai and 5 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Frontiers in cellular and infection microbiology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. [Protective effect of excretory-secretory proteins fromNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Mining Helminths for Novel Therapeutics.Trends in molecular medicine · 2021
    Review
  16. Molecular medicine reports · 2021
    Article
  17. Therapeutic Efficacy of Excretory-Secretory Products ofFrontiers in cellular and infection microbiology · 2021
    Article
  18. Frontiers in cellular and infection microbiology · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Shifang GaoSecond Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Huihui LiAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Hong XieAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Shili WuFirst Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Yuan YuanAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Liang ChuSecond Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Siying SunAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Huijuan YangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Lingqin WuAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Yongsheng BaiAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Qiao ZhouAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Xin WangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China.
Bin ZhanNational School of Tropical Medicine, Baylor College of Medicine, Houston, TX, 77030, USA.
Hu CuiSecond Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China. Ch81598159@163.com.
Xiaodi YangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China. yxd_qf@163.com.
Bengbu Medical College · CNThe Second Affiliated Hospital of Bengbu Medical College · CNBaylor College of Medicine · USFirst Affiliated Hospital of Bengbu Medical College · CN

Funding

Cardiovascular Injury and Protection Foundation and Clinical Application Innovation Team BYKC201906National College Students Innovation and Entrepreneurship Training Program 201810367012National College Students Innovation and Entrepreneurship Training Program 201910367002National College Students Innovation and Entrepreneurship Training Program 201910367025Natural Science Foundation of Anhui Province 2018H174Natural Science Foundation of Anhui Province 201904a07020017Natural Science Foundation of Anhui Province No. gxbjZD15Postgraduate Scientific Research Innovation Program of Bengbu Medical College Byycx1828Postgraduate Scientific Research Innovation Program of Bengbu Medical College Byycx1903Postgraduate Scientific Research Innovation Program of Bengbu Medical College Byycx1920Program of Natural Science Foundation of the Anhui Higher Education Institutions KJ2019A0383Science Foundation of Bengbu Medical College BYTM2019002Scientific Research Innovation Platform Team of University No. 2016-40
6 · The paper itself

Abstract

backgroundMyocardial dysfunction is one of the most common complications of multiple organ failure in septic shock and significantly increases mortality in patients with sepsis. Although many studies having confirmed that helminth-derived proteins have strong immunomodulatory functions and could treat inflammatory diseases, there is no report on the therapeutic effect of Schistosoma japonicum-produced cystatin (Sj-Cys) on sepsis-induced cardiac dysfunction.

methodsA model of sepsis-induced myocardial injury was established by cecal ligation and puncture (CLP) in mice. Upon CLP operation, each mouse was intraperitoneally treated with 10 µg of recombinant Sj-Cys (rSj-Cys). Twelve hours after CLP, the systolic and diastolic functions of the left ventricular were examined by echocardiography. The levels of myoglobin (Mb), cardiac troponin I (cTnI), N-terminal pro-Brain Natriuretic peptide (NT-proBNP) in sera, and the activity of myeloperoxidase (MPO) in cardiac tissues were examined as biomarkers for heart injury. The heart tissue was collected for checking pathological changes, macrophages and pro-inflammatory cytokine levels. To address the signaling pathway involved in the anti-inflammatory effects of rSj-Cys, myeloid differentiation factor 88 (MyD88) was determined in heart tissue of mice with sepsis and LPS-stimulated H9C2 cardiomyocytes. In addition, the therapeutic effects of rSj-Cys on LPS-induced cardiomyocyte apoptosis were also detected. The levels of M1 biomarker iNOS and M2 biomarker Arg-1 were detected in heart tissue. The pro-inflammatory cytokines TNF-α and IL-6, and regulatory cytokines IL-10 and TGF-β were measured in sera and their mRNA levels in heart tissue of rSj-Cys-treated mice.

resultsAfter rSj-Cys treatment, the sepsis-induced heart malfunction was largely improved. The inflammation and injury of heart tissue were significantly alleviated, characterized as significantly decreased infiltration of inflammatory cells in cardiac tissues and fiber swelling, reduced levels of Mb, cTnI and NT-proBNP in sera, and MPO activity in heart tissue. The therapeutic efficacy of rSj-Cys is associated with downregulated pro-inflammatory cytokines (TNF-α and IL-6) and upregulated regulatory inflammatory cytokines (IL-10 and TGF-β), possibly through inhibiting the LPS-MyD88 signal pathway.

conclusionsRSj-Cys significantly reduced sepsis-induced cardiomyopathy and could be considered as a potential therapeutic agent for the prevention and treatment of sepsis associated cardiac dysfunction.

Indexed as

AnimalsCardiomyopathiesCystatinsDisease Models, AnimalHelminth ProteinsImmunologic FactorsMaleMiceMice, Inbred BALB CMyocardiumRecombinant ProteinsSchistosoma japonicumSepsisSpecific Pathogen-Free OrganismsCystatinsHelminth ProteinsImmunologic FactorsRecombinant ProteinsCystatinImmunoregulationMyocardial dysfunctionSchistosoma japonicum

Identifiers

PMID32423469
PMCPMC7236195
OpenAlexW3027341751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.